I placebokontrollerede forsøg var den samlede forekomst af bivirkninger ved brug af telmisartan, (41, 4%) sædvanligvis sammenlignelig med placebo (43, 9%).
The overall incidence of adverse events reported with telmisartan (41.4%) was usually comparable to placebo (43.9%) in placebo controlled trials.